Menu
Search
|

Menu

Close
X

Ironwood Pharmaceuticals Inc IRWD.OQ (NASDAQ Stock Exchange Global Select Market)

10.72 USD
+0.06 (+0.56%)
As of 4:00 PM EDT
Previous Close 10.66
Open 10.64
Volume 405,315
3m Avg Volume 464,153
Today’s High 10.94
Today’s Low 10.59
52 Week High 20.32
52 Week Low 9.16
Shares Outstanding (mil) 149.59
Market Capitalization (mil) 2,604.40
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.30 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
69
FY18
347
FY17
298
FY16
274
EPS (USD)
FY19
-0.383
FY18
-1.849
FY17
-0.789
FY16
-0.564
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
9.62
7.92
Price to Book (MRQ)
vs sector
534.65
5.38
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
8,068.93
14.56
LT Debt to Equity (MRQ)
vs sector
7,964.27
10.21
Return on Investment (TTM)
vs sector
-23.24
14.49
Return on Equity (TTM)
vs sector
-332.60
15.79

EXECUTIVE LEADERSHIP

Julie McHugh
Independent Chairman of the Board, Since 2019
Salary: --
Bonus: --
Mark Mallon
Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Gina Consylman
Chief Financial Officer, Senior Vice President, Since 2017
Salary: $415,000.00
Bonus: $207,500.00
William Huyett
Chief Operating Officer, Since 2017
Salary: $465,000.00
Bonus: $232,500.00
Thomas McCourt
Senior Vice President - Marketing and Sales, Chief Commercial Officer, Since 2009
Salary: $465,000.00
Bonus: $232,500.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

301 Binney St
CAMBRIDGE   MA   02142-1030

Phone: +1617.6217722

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

SPONSORED STORIES